How to Buy smspharma Shares on Fincept?
You can buy SMS Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: SMS Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Smspharma, including updates on board meetings and corporate actions.
SMS Pharmaceuticals Limited - https://smspharma.com
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. The company offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
SMS Pharmaceuticals Limited Share Price Today
199.41
OPEN
205.50
HIGH
197.91
LOW
200.02
CLOSE
88 K
VOLUME
1,989 Cr
Market Cap
212927
Average Volume
Healthcare
Sector
NSI
Exchange
SMS Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: SMSPHARMA Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
SMS Pharmaceuticals Limited |
SMSPHARMA |
INE812G01017 |
Dividend - Rs 0.40 Per Share |
23 Sep 2024 |
1 |
N/A |
SMS Pharmaceuticals Limited |
SMSPHARMA |
INE812G01017 |
Annual General Meeting |
23 Sep 2024 |
1 |
N/A |
SMS Pharmaceuticals Limited |
SMSPHARMA |
INE812G01017 |
Dividend - Re 0.30 Per Share |
22 Sep 2023 |
1 |
N/A |
SMS Pharmaceuticals Limited |
SMSPHARMA |
INE812G01017 |
Annual General Meeting |
22 Sep 2023 |
1 |
N/A |
SMS Pharmaceuticals Limited |
SMSPHARMA |
INE812G01017 |
Dividend - Re 0.30 Per Share |
22 Sep 2022 |
1 |
N/A |
NSE: SMSPHARMA Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
SMSPHARMA |
28 Dec 2024, 11:20:33 |
Trading Window-XBRL |
Pharmaceuticals |
SMSPHARMA |
28 Dec 2024, 11:16:25 |
Trading Window |
Pharmaceuticals |
SMSPHARMA |
22 Nov 2024, 19:44:12 |
General Updates |
Pharmaceuticals |
SMSPHARMA |
15 Nov 2024, 19:09:52 |
Analysts/Institutional Investor Meet/Con. Call Updates |
Pharmaceuticals |
SMSPHARMA |
13 Nov 2024, 17:24:05 |
Analysts/Institutional Investor Meet/Con. Call Updates |
Pharmaceuticals |
NSE: SMSPHARMA Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
SMS Pharmaceuticals Limited |
SMSPHARMA |
18 Oct 2024, 17:52:00 |
18 Oct 2024, 17:53:00 |
|
SMS Pharmaceuticals Limited |
SMSPHARMA |
05 Jul 2024, 15:01:00 |
05 Jul 2024, 15:01:00 |
|
SMS Pharmaceuticals Limited |
SMSPHARMA |
16 Apr 2024, 10:16:00 |
16 Apr 2024, 10:45:00 |
|
SMS Pharmaceuticals Limited |
SMSPHARMA |
06 Jan 2024, 10:45:00 |
06 Jan 2024, 11:15:00 |
|
SMS Pharmaceuticals Limited |
SMSPHARMA |
18 Oct 2023, 19:45:00 |
18 Oct 2023, 20:15:00 |
NSE: SMSPHARMA Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Executive Director-MD |
23 Jun 1959 |
30 Aug 1990 |
00166381 |
Ramesh Babu Potluri |
Active |
Independent Director |
15 Aug 1957 |
30 Sep 2014 |
01456746 |
Pakalapati Sarath Kumar |
Active |
Independent Director |
28 Apr 1978 |
20 Sep 2018 |
06905851 |
Shravan Kudaravalli |
Active |
Independent Director |
29 Jun 1962 |
12 Aug 2019 |
02292051 |
Sarvepalli Srinivas |
Active |
Independent Director |
01 Jul 1963 |
30 Sep 2014 |
00065571 |
Thummala Neelaveni |
Active |
NSE: SMSPHARMA Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
SMSPHARMA |
N/A |
INE812G01017 |
SMS Pharmaceuticals Limited |
01 Nov 2024, 16:10:23 |
SMS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Aug-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2024 and Other business. |
SMSPHARMA |
N/A |
INE812G01017 |
SMS Pharmaceuticals Limited |
29 Jul 2024, 17:05:22 |
Financial Results/Dividend/Other business matters |
SMSPHARMA |
N/A |
INE812G01017 |
SMS Pharmaceuticals Limited |
22 May 2024, 15:11:55 |
SMS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 08-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2023 and Other business. |
SMSPHARMA |
N/A |
INE812G01017 |
SMS Pharmaceuticals Limited |
02 Feb 2024, 15:50:03 |
Financial Results/Other business matters |
SMSPHARMA |
N/A |
INE812G01017 |
SMS Pharmaceuticals Limited |
01 Nov 2023, 18:14:09 |
NSE: SMSPHARMA Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results/Other business matters |
SMSPHARMA |
- |
INE812G01017 |
SMS Pharmaceuticals Limited |
01 Nov 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
Financial Results/Other business matters |
SMSPHARMA |
- |
INE812G01017 |
SMS Pharmaceuticals Limited |
02 Aug 2024, 00:00:00 |
The Company has informed the Exchange that the venue of the Board Meeting has been changed to the Registered Office of the Company situated at Plot No. 72, H.No. 8-2-334/3&4, Road No.5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad, Telangana 500034 instead of manufacturing facility. Please note that the date of the meeting remains unchanged. |
Financial Results/Other business matters |
SMSPHARMA |
- |
INE812G01017 |
SMS Pharmaceuticals Limited |
29 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 and other business matters |
Financial Results/Dividend/Other business matters |
SMSPHARMA |
- |
INE812G01017 |
SMS Pharmaceuticals Limited |
22 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024, dividend and other business matters |
Financial Results/Other business matters |
SMSPHARMA |
- |
INE812G01017 |
SMS Pharmaceuticals Limited |
02 Feb 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 and other business matters |
NSE: SMSPHARMA Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Investmentin Financial Assets | Available For Sale Securities | Long Term Equity Investment | Investmentsin Associatesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,762,695,000.00 | 2,853,432,000.00 | 5,610,859,000.00 | 8,487,199,000.00 | 2,065,434,000.00 | 5,610,859,000.00 | 1,731,000.00 | 5,635,498,000.00 | 7,141,630,000.00 | 5,635,498,000.00 | 5,635,498,000.00 | 5,550,846,000.00 | 0.00 | 0.00 | 84,652,000.00 | 84,652,000.00 | 5,711,784,000.00 | 1,957,796,000.00 | 0.00 | 439,364,000.00 | 1,506,132,000.00 | 0.00 | 1,506,132,000.00 | 12,300,000.00 | 3,753,988,000.00 | 56,979,000.00 | 1,347,300,000.00 | 1,731,000.00 | 1,345,569,000.00 | 0.00 | 10,660,000.00 | 2,151,316,000.00 | 0.00 | 0.00 | 2,151,316,000.00 | 11,347,282,000.00 | 5,527,860,000.00 | 123,680,000.00 | 0.00 | 195,483,000.00 | 195,483,000.00 | 0.00 | 0.00 | 24,639,000.00 | 0.00 | 5,184,058,000.00 | 0.00 | 5,184,058,000.00 | 944,964,000.00 | 4,239,094,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5,819,422,000.00 | 311,285,000.00 | 0.00 | 0.00 | 3,152,716,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12,722,000.00 | 2,133,788,000.00 | 0.00 | 0.00 | 208,911,000.00 | 119,905,000.00 | 89,006,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | annual | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,441,392,000.00 | 2,807,705,000.00 | 5,336,694,000.00 | 8,165,076,000.00 | 2,021,764,000.00 | 5,336,694,000.00 | 5,918,000.00 | 5,363,289,000.00 | 6,584,152,000.00 | 5,363,289,000.00 | 5,363,289,000.00 | 285,750,000.00 | 3,248,775,000.00 | 713,684,000.00 | 84,652,000.00 | 84,652,000.00 | 4,977,637,000.00 | 1,660,453,000.00 | 11,601,000.00 | 427,989,000.00 | 1,220,863,000.00 | 0.00 | 1,220,863,000.00 | 11,601,000.00 | 3,317,184,000.00 | 48,295,000.00 | 1,586,842,000.00 | 5,918,000.00 | 1,580,924,000.00 | 10,304,000.00 | 10,304,000.00 | 1,700,269,000.00 | 186,177,000.00 | 865,000.00 | 1,513,227,000.00 | 10,340,926,000.00 | 5,001,978,000.00 | 138,712,000.00 | 51,705,000.00 | 187,966,000.00 | 187,966,000.00 | 109,378,000.00 | 109,378,000.00 | 26,595,000.00 | 26,595,000.00 | 4,787,417,000.00 | -1,897,109,000.00 | 6,684,526,000.00 | 441,429,000.00 | 282,888,000.00 | 4,576,993,000.00 | 1,341,086,000.00 | 42,130,000.00 | 0.00 | 5,338,948,000.00 | 227,545,000.00 | 865,000.00 | 149,447,000.00 | 2,336,978,000.00 | 6,747,000.00 | 548,189,000.00 | 904,659,000.00 | 877,383,000.00 | 18,307,000.00 | 110,624,000.00 | 2,362,332,000.00 | -1,049,000.00 | 2,363,381,000.00 | 360,395,000.00 | 34,416,000.00 | 360,395,000.00 | 0.00 | 360,395,000.00 |
| 2024-03-31T00:00:00 | quarterly | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,441,392,000.00 | 2,807,705,000.00 | 5,336,694,000.00 | 8,165,076,000.00 | 2,021,764,000.00 | 5,336,694,000.00 | 5,918,000.00 | 5,363,289,000.00 | 6,584,152,000.00 | 5,363,289,000.00 | 5,363,289,000.00 | 285,750,000.00 | 3,248,775,000.00 | 713,684,000.00 | 84,652,000.00 | 84,652,000.00 | 4,977,637,000.00 | 1,660,453,000.00 | 11,601,000.00 | 427,989,000.00 | 1,220,863,000.00 | 0.00 | 1,220,863,000.00 | 11,601,000.00 | 3,317,184,000.00 | 48,295,000.00 | 1,586,842,000.00 | 5,918,000.00 | 1,580,924,000.00 | 10,304,000.00 | 10,304,000.00 | 1,700,269,000.00 | 186,177,000.00 | 865,000.00 | 1,513,227,000.00 | 10,340,926,000.00 | 5,001,978,000.00 | 138,712,000.00 | 51,705,000.00 | 187,966,000.00 | 187,966,000.00 | 109,378,000.00 | 109,378,000.00 | 26,595,000.00 | 26,595,000.00 | 4,787,417,000.00 | -1,897,109,000.00 | 6,684,526,000.00 | 441,429,000.00 | 282,888,000.00 | 4,576,993,000.00 | 1,341,086,000.00 | 42,130,000.00 | 0.00 | 5,338,948,000.00 | 227,545,000.00 | 865,000.00 | 149,447,000.00 | 2,336,978,000.00 | 6,747,000.00 | 548,189,000.00 | 904,659,000.00 | 877,383,000.00 | 18,307,000.00 | 110,624,000.00 | 2,362,332,000.00 | -1,049,000.00 | 2,363,381,000.00 | 360,395,000.00 | 34,416,000.00 | 360,395,000.00 | 0.00 | 360,395,000.00 |
| 2023-09-30T00:00:00 | quarterly | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,427,837,000.00 | 2,766,852,000.00 | 4,772,573,000.00 | 7,545,711,000.00 | 1,588,944,000.00 | 4,772,573,000.00 | 10,688,000.00 | 4,789,547,000.00 | 5,926,771,000.00 | 4,789,547,000.00 | 4,789,547,000.00 | 4,704,895,000.00 | 0.00 | 0.00 | 84,652,000.00 | 84,652,000.00 | 4,981,162,000.00 | 1,566,821,000.00 | 0.00 | 415,065,000.00 | 1,138,094,000.00 | 870,000.00 | 1,137,224,000.00 | 13,662,000.00 | 3,414,341,000.00 | 49,842,000.00 | 1,628,758,000.00 | 9,818,000.00 | 1,618,940,000.00 | 0.00 | 10,103,000.00 | 1,591,976,000.00 | 0.00 | 0.00 | 1,591,976,000.00 | 9,770,709,000.00 | 4,767,424,000.00 | 94,235,000.00 | 0.00 | 179,409,000.00 | 179,409,000.00 | 0.00 | 0.00 | 16,974,000.00 | 0.00 | 4,476,806,000.00 | 0.00 | 4,476,806,000.00 | 428,610,000.00 | 4,048,196,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5,003,285,000.00 | 245,956,000.00 | 0.00 | 0.00 | 2,774,413,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 53,427,000.00 | 1,543,882,000.00 | 0.00 | 0.00 | 385,607,000.00 | 57,280,000.00 | 328,327,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | annual | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,452,056,000.00 | 2,540,669,000.00 | 4,590,596,000.00 | 7,130,386,000.00 | 1,557,351,000.00 | 4,590,596,000.00 | 15,535,000.00 | 4,605,252,000.00 | 5,816,585,000.00 | 4,605,252,000.00 | 4,605,252,000.00 | 4,520,600,000.00 | 2,876,488,000.00 | 713,684,000.00 | 84,652,000.00 | 84,652,000.00 | 4,190,849,000.00 | 1,641,714,000.00 | 14,045,000.00 | 410,200,000.00 | 1,217,469,000.00 | 6,136,000.00 | 1,211,333,000.00 | 14,045,000.00 | 2,549,135,000.00 | 15,248,000.00 | 1,323,200,000.00 | 9,399,000.00 | 1,313,801,000.00 | 10,420,000.00 | 10,420,000.00 | 1,203,987,000.00 | 128,772,000.00 | 918,000.00 | 1,074,297,000.00 | 8,796,101,000.00 | 4,689,615,000.00 | 56,104,000.00 | 50,850,000.00 | 181,431,000.00 | 181,431,000.00 | 105,220,000.00 | 105,220,000.00 | 14,656,000.00 | 14,656,000.00 | 4,493,528,000.00 | -1,601,670,000.00 | 6,095,198,000.00 | 388,009,000.00 | 119,261,000.00 | 4,237,987,000.00 | 1,307,811,000.00 | 42,130,000.00 | 0.00 | 4,106,486,000.00 | 189,697,000.00 | 918,000.00 | 135,417,000.00 | 2,234,994,000.00 | 5,570,000.00 | 383,826,000.00 | 1,059,022,000.00 | 786,576,000.00 | 13,401,000.00 | 165,216,000.00 | 1,483,462,000.00 | -1,049,000.00 | 1,484,511,000.00 | 73,078,000.00 | 66,930,000.00 | 73,078,000.00 | 700,000.00 | 73,078,000.00 |
| 2023-03-31T00:00:00 | quarterly | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,452,056,000.00 | 2,540,669,000.00 | 4,590,596,000.00 | 7,130,386,000.00 | 1,557,351,000.00 | 4,590,596,000.00 | 15,535,000.00 | 4,605,252,000.00 | 5,816,585,000.00 | 4,605,252,000.00 | 4,605,252,000.00 | 4,520,600,000.00 | 2,876,488,000.00 | 713,684,000.00 | 84,652,000.00 | 84,652,000.00 | 4,190,849,000.00 | 1,641,714,000.00 | 14,045,000.00 | 410,200,000.00 | 1,217,469,000.00 | 6,136,000.00 | 1,211,333,000.00 | 14,045,000.00 | 2,549,135,000.00 | 15,248,000.00 | 1,323,200,000.00 | 9,399,000.00 | 1,313,801,000.00 | 10,420,000.00 | 10,420,000.00 | 1,203,987,000.00 | 128,772,000.00 | 918,000.00 | 1,074,297,000.00 | 8,796,101,000.00 | 4,689,615,000.00 | 56,104,000.00 | 50,850,000.00 | 181,431,000.00 | 181,431,000.00 | 105,220,000.00 | 105,220,000.00 | 14,656,000.00 | 14,656,000.00 | 4,493,528,000.00 | -1,601,670,000.00 | 6,095,198,000.00 | 388,009,000.00 | 119,261,000.00 | 4,237,987,000.00 | 1,307,811,000.00 | 42,130,000.00 | 0.00 | 4,106,486,000.00 | 189,697,000.00 | 918,000.00 | 135,417,000.00 | 2,234,994,000.00 | 5,570,000.00 | 383,826,000.00 | 1,059,022,000.00 | 786,576,000.00 | 13,401,000.00 | 165,216,000.00 | 1,483,462,000.00 | -1,049,000.00 | 1,484,511,000.00 | 73,078,000.00 | 66,930,000.00 | 73,078,000.00 | 700,000.00 | 73,078,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,135,309,000.00 | 2,632,685,000.00 | 4,689,185,000.00 | 7,304,023,000.00 | 1,805,708,000.00 | 4,689,185,000.00 | 31,548,000.00 | 4,702,886,000.00 | 6,197,901,000.00 | 4,702,886,000.00 | 4,702,886,000.00 | 4,618,234,000.00 | 2,974,122,000.00 | 713,684,000.00 | 84,652,000.00 | 84,652,000.00 | 3,892,131,000.00 | 1,927,328,000.00 | 15,662,000.00 | 395,507,000.00 | 1,516,159,000.00 | 21,144,000.00 | 1,495,015,000.00 | 17,592,000.00 | 1,964,803,000.00 | 26,809,000.00 | 1,116,526,000.00 | 10,404,000.00 | 1,106,122,000.00 | 10,164,000.00 | 8,235,000.00 | 798,764,000.00 | 69,413,000.00 | 773,000.00 | 728,578,000.00 | 8,595,017,000.00 | 4,824,506,000.00 | 43,006,000.00 | 50,225,000.00 | 291,546,000.00 | 291,546,000.00 | 215,271,000.00 | 215,271,000.00 | 13,701,000.00 | 13,701,000.00 | 4,519,258,000.00 | -1,296,093,000.00 | 5,815,351,000.00 | 153,045,000.00 | 131,883,000.00 | 4,187,822,000.00 | 1,300,471,000.00 | 42,130,000.00 | 0.00 | 3,770,511,000.00 | 260,495,000.00 | 773,000.00 | 113,675,000.00 | 2,510,975,000.00 | 7,467,000.00 | 614,238,000.00 | 1,189,455,000.00 | 699,815,000.00 | 35,322,000.00 | 158,745,000.00 | 485,193,000.00 | -1,049,000.00 | 486,242,000.00 | 465,828,000.00 | 3,530,000.00 | 465,828,000.00 | 120,000,000.00 | 345,828,000.00 |
| 2021-03-31T00:00:00 | annual | 0.00 | 84,652,030.00 | 84,652,030.00 | 2,100,922,000.00 | 2,545,788,000.00 | 4,089,256,000.00 | 6,610,433,000.00 | 1,138,995,000.00 | 4,089,256,000.00 | 40,635,000.00 | 4,105,280,000.00 | 5,579,358,000.00 | 4,105,280,000.00 | 4,105,280,000.00 | 4,020,629,000.00 | 2,476,516,000.00 | 713,684,000.00 | 84,652,000.00 | 84,652,000.00 | 4,016,848,000.00 | 2,062,554,000.00 | 18,399,000.00 | 538,530,000.00 | 1,505,625,000.00 | 31,547,000.00 | 1,474,078,000.00 | 18,399,000.00 | 1,954,294,000.00 | 33,521,000.00 | 1,040,163,000.00 | 9,088,000.00 | 1,031,075,000.00 | 8,235,000.00 | 8,235,000.00 | 825,775,000.00 | 170,506,000.00 | 867,000.00 | 654,402,000.00 | 8,122,128,000.00 | 5,028,839,000.00 | 56,328,000.00 | 34,643,000.00 | 331,444,000.00 | 331,444,000.00 | 273,028,000.00 | 273,028,000.00 | 16,024,000.00 | 16,024,000.00 | 4,681,372,000.00 | -991,681,000.00 | 5,673,053,000.00 | 123,765,000.00 | 139,907,000.00 | 4,134,419,000.00 | 1,232,832,000.00 | 42,130,000.00 | 0.00 | 3,093,289,000.00 | 1,000.00 | 867,000.00 | 77,805,000.00 | 1,377,873,000.00 | 2,547,000.00 | 444,503,000.00 | 234,142,000.00 | 696,681,000.00 | 10,932,000.00 | 164,782,000.00 | 1,056,798,000.00 | -1,049,000.00 | 1,057,847,000.00 | 404,231,000.00 | 4,483,000.00 | 404,231,000.00 | 175,000,000.00 | 229,231,000.00 |
NSE: SMSPHARMA Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Payments | Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Net Investment Purchase And Sale | Purchase Of Investment | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Prepaid Assets | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Pension And Employee Benefit Expense | Gain Loss On Investment Securities | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -20,353,000.00 | -377,636,000.00 | 652,934,000.00 | 284,778,000.00 | -521,600,000.00 | 360,395,000.00 | 0.00 | 73,078,000.00 | 287,317,000.00 | 306,790,000.00 | 0.00 | -217,516,000.00 | -25,396,000.00 | 0.00 | 284,778,000.00 | 284,778,000.00 | 275,298,000.00 | 202,071,000.00 | 0.00 | 202,071,000.00 | 73,227,000.00 | -377,636,000.00 | 450,863,000.00 | -520,720,000.00 | -1,522,000.00 | 1,587,000.00 | -65,000.00 | -65,000.00 | -520,720,000.00 | 880,000.00 | -521,600,000.00 | 501,247,000.00 | -154,000,000.00 | -545,478,000.00 | 41,744,000.00 | -88,509,000.00 | 438,677,000.00 | 43,064,000.00 | -101,984,000.00 | -878,470,000.00 | 224,657,000.00 | 0.00 | 315,157,000.00 | 9,116,000.00 | 306,041,000.00 | -2,033,000.00 | -373,000.00 | 661,068,000.00 |
| 2023-03-31T00:00:00 | annual | -74,707,000.00 | -430,579,000.00 | 352,908,000.00 | 0.00 | -299,207,000.00 | 73,778,000.00 | 700,000.00 | 465,828,000.00 | -392,750,000.00 | -319,689,000.00 | 0.00 | -209,276,000.00 | -25,396,000.00 | 0.00 | 0.00 | 0.00 | -77,671,000.00 | 258,771,000.00 | 0.00 | 258,771,000.00 | -336,442,000.00 | -430,579,000.00 | 94,137,000.00 | -297,561,000.00 | -888,000.00 | 1,581,000.00 | -1,680,000.00 | -1,680,000.00 | -296,574,000.00 | 2,633,000.00 | -299,207,000.00 | 224,500,000.00 | -46,000,000.00 | -312,894,000.00 | -43,134,000.00 | -4,752,000.00 | 424,373,000.00 | 32,907,000.00 | 275,981,000.00 | -998,269,000.00 | 209,514,000.00 | 0.00 | 321,254,000.00 | 7,087,000.00 | 314,167,000.00 | -3,414,000.00 | 544,000.00 | 53,491,000.00 |
| 2022-03-31T00:00:00 | annual | 178,123,000.00 | -366,713,000.00 | 460,788,000.00 | 0.00 | -272,474,000.00 | 465,828,000.00 | -1,000.00 | 404,231,000.00 | 61,597,000.00 | -117,470,000.00 | -1,000.00 | -177,062,000.00 | -25,395,000.00 | 0.00 | 0.00 | 0.00 | 94,075,000.00 | -29,464,000.00 | -38,353,000.00 | 8,889,000.00 | 123,539,000.00 | -328,360,000.00 | 451,899,000.00 | -271,530,000.00 | -1,983,000.00 | 2,756,000.00 | 0.00 | 0.00 | -272,303,000.00 | 171,000.00 | -272,474,000.00 | 450,597,000.00 | -149,204,000.00 | -583,754,000.00 | -39,952,000.00 | -41,897,000.00 | 74,176,000.00 | -14,584,000.00 | -1,133,102,000.00 | 571,605,000.00 | 175,918,000.00 | 0.00 | 321,525,000.00 | 7,100,000.00 | 314,425,000.00 | -415,000.00 | -20,000.00 | 684,991,000.00 |
| 2021-03-31T00:00:00 | annual | -612,956,000.00 | -192,923,000.00 | 1,174,540,000.00 | 0.00 | -1,517,490,000.00 | 404,231,000.00 | 0.00 | 95,442,000.00 | 308,789,000.00 | 920,178,000.00 | 1,000.00 | -61,439,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 981,617,000.00 | 97,033,000.00 | -20,223,000.00 | 117,256,000.00 | 884,584,000.00 | -172,700,000.00 | 1,057,284,000.00 | -1,515,923,000.00 | -1,662,000.00 | 1,898,000.00 | 0.00 | 0.00 | -1,516,159,000.00 | 1,331,000.00 | -1,517,490,000.00 | 904,534,000.00 | -160,463,000.00 | -123,784,000.00 | -29,233,000.00 | 350,604,000.00 | 209,461,000.00 | 1,130,000.00 | -85,871,000.00 | -569,875,000.00 | 53,482,000.00 | 784,000.00 | 222,816,000.00 | 4,337,000.00 | 218,479,000.00 | 523,000.00 | -22,000.00 | 911,198,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,000.00 | 0.00 | 0.00 | 0.00 | -1,000.00 | 0.00 | -51,026,000.00 | -51,026,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -216,489,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: SMSPHARMA Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Research And Development | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 0.01 | 0.00 | 120.20 | 0.04 | 0.04 | 49.83 | 31.52 | 497.71 | 120.24 | 88.72 | -22.84 | 22.62 | 0.76 | 49.80 | 49.83 | 621.21 | 0.07 | 8.47 | 8.47 | 0.00 | 0.00 | 49.83 | 49.83 | 0.00 | 49.83 | 49.83 | 49.83 | 16.91 | 66.11 | 0.76 | 0.04 | -0.04 | -22.84 | 0.98 | 22.62 | 0.76 | 85.25 | 123.50 | 5.25 | 31.52 | 0.91 | 30.60 | 11.11 | 14.21 | 4.73 | 9.47 | 0.07 | 208.75 | 497.71 | 706.46 | 706.46 |
| 2023-03-31T00:00:00 | annual | -0.01 | 0.00 | 58.52 | -0.05 | -0.05 | -7.06 | 32.13 | 390.61 | 58.47 | 26.34 | -21.20 | 20.99 | 0.77 | -7.02 | -7.06 | 497.27 | 0.08 | 8.47 | 8.47 | 0.00 | 0.00 | -7.06 | -7.06 | 0.00 | -7.06 | -7.06 | -7.06 | 1.47 | 5.35 | 0.22 | -0.05 | 0.05 | -21.20 | 0.98 | 20.99 | 0.77 | 22.48 | 106.66 | 4.69 | 32.13 | 0.71 | 31.42 | 8.92 | 9.32 | 3.82 | 5.50 | 0.08 | 129.14 | 390.61 | 519.75 | 519.75 |
| 2022-03-31T00:00:00 | annual | 0.00 | 0.00 | 118.81 | 0.00 | 0.00 | 62.22 | 32.15 | 333.59 | 118.81 | 86.66 | -18.60 | 18.16 | 0.56 | 62.22 | 62.22 | 432.55 | 0.09 | 8.47 | 8.47 | 0.00 | 0.00 | 62.22 | 62.22 | 0.00 | 62.22 | 62.22 | 62.22 | 0.62 | 68.50 | 2.06 | 0.00 | 0.00 | -18.60 | 1.01 | 18.16 | 0.56 | 82.47 | 98.96 | 4.55 | 32.15 | 0.71 | 31.44 | 0.00 | 8.37 | 3.42 | 4.95 | 0.09 | 181.43 | 333.59 | 515.02 | 515.02 |
| 2021-03-31T00:00:00 | annual | 0.00 | 0.00 | 123.66 | -0.01 | -0.01 | 62.53 | 22.28 | 379.39 | 123.66 | 101.37 | -10.87 | 10.25 | 0.31 | 62.53 | 62.53 | 461.95 | 0.10 | 8.47 | 8.47 | 0.00 | 0.00 | 62.53 | 62.53 | 0.00 | 62.53 | 62.53 | 62.53 | 30.16 | 91.12 | 2.57 | -0.01 | 0.01 | -10.87 | 0.94 | 10.25 | 0.31 | 98.86 | 82.56 | 3.58 | 22.28 | 0.43 | 21.85 | 0.00 | 9.20 | 5.09 | 4.11 | 0.10 | 181.43 | 379.39 | 560.82 | 560.82 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
7.02
P/E
33.411682
P/B
3.7020378
Dividend Yield
0.13%
Market Cap
1,988.94 Cr.
Face Value
63.357
Book Value
63.357
ROE
7.72%
EBITDA Growth
123.27 Cr.
Debt/Equity
52.35
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of smspharma?
The market capitalization of SMS Pharmaceuticals Limited is ₹1,989 Cr as of 05 Feb 2025.
What are the PE and PB ratios of SMS Pharmaceuticals Limited?
The PE and PB ratios of SMS Pharmaceuticals Limited are Not Available and 3.7020378 respectively as of 05 Feb 2025.
What is the 52 Week High of SMS Pharmaceuticals Limited?
The 52-week high of SMS Pharmaceuticals Limited is ₹398 as of 05 Feb 2025.
What is the 52 Week Low of SMS Pharmaceuticals Limited?
The 52-week low of SMS Pharmaceuticals Limited is ₹117.9 as of 05 Feb 2025.
What are the earnings per share (EPS) for SMS Pharmaceuticals Limited?
The Earnings Per Share (EPS) of SMS Pharmaceuticals Limited is ₹7.02 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of SMS Pharmaceuticals Limited?
The Return on Equity (ROE) of SMS Pharmaceuticals Limited is 7.72% as per the most recent financial year data. Explore more on Fincept.